Nektar Therapeutics

The current institutional shareholding score of Nektar Therapeutics is 5.00, ranking 132 out of 385 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 61.39%, representing a quarter-over-quarter decrease of 16.36%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.14% of shares outstanding, with 13.18% increase in holdings.